ACTOPLUS MET

This brand name is authorized in United States.

Active ingredients

The drug ACTOPLUS MET contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Pioglitazone UNII `JQT35NPK6C` - PIOGLITAZONE HYDROCHLORIDE
	Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.
	Read more about Pioglitazone
`2`	Metformin UNII `786Z46389E` - METFORMIN HYDROCHLORIDE
	Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.
	Read more about Metformin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ACTOPLUS MET XR Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	64764-155, 64764-158, 64764-310, 64764-510

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.